NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has received a Complete Response Letter (CRL)…Original Article
You may also like
Mi pesadilla con el virus del Nilo Occidental
U.S. Races to Replace IV Fluid Supplies After...
Zantac’s Developer Settles Lawsuits Claiming Cancer...
On Drug Prices, Harris Pushes for Deeper Cuts While...
Ascendis Pharma Announces Extension of U.S. Food and...
Eton Pharmaceuticals Announces Submission to FDA of...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.